Lamuna® 20

Desogestrel/Ethinylestradiol, the active ingredients in Lamuna® 20, are a combined oral contraceptive presented as a 150 µg / 20 µg tablet for oral use. This drug class works by inhibiting ovulation and altering cervical mucus, providing reliable birth control for women of reproductive age.

GNH USA supplies Lamuna® 20 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Lamuna® 20, a combined oral contraceptive, is used in the hormonal regulation of reproductive function.

Contraception: prevention of pregnancy by suppressing ovulation. Menstrual cycle regulation: reduction of irregular bleeding and cycle stabilization. Acne management: improvement of hormonally‑responsive acne. Polycystic ovary syndrome (PCOS): assistance in regularizing menstrual cycles and reducing androgenic symptoms.

Lamuna® 20 may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea or gastrointestinal discomfort. - Breast tenderness or enlargement. - Headache or migraine. - Spotting or breakthrough bleeding. - Mood changes or irritability. - Weight fluctuation.

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism). - Arterial thrombosis (stroke, myocardial infarction). - Severe hypertension or hypertensive crisis. - Liver adenoma or other hepatic neoplasms. - Anaphylactic or severe allergic reaction.

Before prescribing Lamuna® 20, clinicians should consider several precautionary measures to ensure patient safety.

Contraindications: do not use in women with known thromboembolic disorders, active liver disease, or hormone‑sensitive cancers. Smoking: avoid in patients over 35 who smoke, as cardiovascular risk increases. History of hypertension: monitor blood pressure regularly. Medication review: assess concomitant use of enzyme‑inducing drugs that may reduce efficacy. Pregnancy and lactation: product is contraindicated in pregnancy (Category X) and not recommended while breastfeeding. Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Lamuna® 20 can interact with several medicines, affecting its contraceptive efficacy or safety.

Major Interactions (Avoid): - Strong enzyme inducers such as carbamazepine, phenytoin, or phenobarbital. - Rifampin or other rifamycin antibiotics. - St. John's Wort (hypericum perforatum).

Moderate Interactions (Monitor Closely): - Antifungal agents like ketoconazole or itraconazole. - Certain antibiotics (e.g., tetracycline, metronidazole) that may modestly reduce plasma hormone levels. - Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline). - Protease inhibitors used in HIV therapy.